Redundancy between Cysteine Cathepsins in Murine Experimental Autoimmune Encephalomyelitis

Euan Ramsay Orr Allan¹, Robin Michael Yates¹,²*

¹ Department of Comparative Biology and Experimental Medicine, Faculty of Veterinary Medicine, University of Calgary, Alberta, Canada, ² Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Calgary, Alberta, Canada

* rmyates@ucalgary.ca

Abstract

The cysteine cathepsins B, S, and L are functionally linked to antigen processing, and hence to autoimmune disorders such as multiple sclerosis. Stemming from several studies that demonstrate that mice can be protected from experimental autoimmune encephalomyelitis (EAE) through the pharmacologic inhibition of cysteine cathepsins, it has been suggested that targeting these enzymes in multiple sclerosis may be of therapeutic benefit. Utilizing mice deficient in cysteine cathepsins both individually and in combination, we found that the myelin-associated antigen myelin oligodendrocyte glycoprotein (MOG) was efficiently processed and presented by macrophages to CD4+ T cells in the individual absence of cathepsin B, S or L. Similarly, mice deficient in cathepsin B or S were susceptible to MOG-induced EAE and displayed clinical progression and immune infiltration into the CNS, similar to their wild-type counterparts. Owing to a previously described CD4+ T cell deficiency in mice deficient in cathepsin L, such mice were protected from EAE. When multiple cysteine cathepsins were simultaneously inhibited via genetic deletion of both cathepsins B and S, or by a cathepsin inhibitor (LHVS), MHC-II surface expression, MOG antigen presentation and EAE were attenuated or prevented. This study demonstrates the functional redundancy between cathepsin B, S and L in EAE, and suggests that the inhibition of multiple cysteine cathepsins may be needed to modulate autoimmune disorders such as multiple sclerosis.

Introduction

Lysosomal cysteine cathepsins are a family of papain-like proteases that are principally charged with the hydrolysis of proteins and the activation of other proteases within endosomes and lysosomes [1–3]. These proteases are highly expressed in antigen presenting cells (APCs), and are critical for the processing of antigens as well as MHC- class II (MHC-II) invariant chain (II) within the endolysosomal system of these cells [3–14]. Unsurprisingly, lysosomal cysteine cathepsins (particularly cathepsin B, S, and L) have been implicated in the processing of
autoantigens and thus associated with the pathogenesis of a multitude of autoimmune conditions (for review see: Vasiljeva et al. 2007) [1–3, 7, 10, 15–20].

Multiple Sclerosis (MS) is a complex inflammatory disease of the central nervous system (CNS) which is characterized by debilitating neurologic impairments that stem from chronic CNS inflammation, extensive demyelination, and lesion formation. The clinical and pathological progression of MS is driven by an autoimmune reaction of CNS-infiltrating myelin-specific autoreactive lymphocytes [21]. The initial infiltration precedes widespread activation of macrophages and microglia in and around the CNS, in parallel with continued and extensive immune infiltration of autoreactive lymphocytes and macrophages [21–23]. Experimental autoimmune encephalomyelitis (EAE) is the most commonly-used animal model for examining the immune processes associated with MS [22]. In C57BL/6 mice, EAE is a CD4+ T cell driven autoimmune disease in response to peripheral inoculation with myelin oligodendrocyte glycoprotein (MOG) protein or peptide [24]. Within the CNS, myelin debris is primarily phagocytosed by infiltrating macrophages (rather than dendritic cells or microglia) [23], proteolytically processed in the endosomal-lysosomal system, and presented on MHC-II to MOG35-55-specific CD4+ T cells. During this process, cysteine cathepsins are believed to be intimately involved in the processing of both the myelin-associated antigens and Ii of MHC-II. Several studies have shown that cathepsin S inhibitors can attenuate EAE and other autoimmune models, suggesting that cathepsin S may be a specific therapeutic target for MS [10, 16, 25–27]. In particular, the compound LHVS has been suggested to selectively inhibit cathepsin S and attenuate EAE [12, 16].

Despite years of interest in therapeutically targeting cysteine cathepsins in MS, and sporadic autoimmune clinical trials of lead compounds that inhibit cathepsin S [27], EAE has not been attempted in mice genetically deficient in individual cysteine cathepsins. Hence, the importance of cathepsins B, S, and L as specific therapeutic targets for MS remain unsubstantiated in an animal model. In the present study, we demonstrate that bone marrow derived macrophages (BMMØs) deficient in cathepsin B, S, or L are equally efficient at presenting MOG to CD4+ T cells. Correspondingly, we show that mice deficient in either cathepsin B or S are not clinically or immunologically protected from EAE, and that a cysteine cathepsin inhibitor (previously proposed to attenuate EAE through selective inhibition of cathepsin S) prevents EAE in a cathepsin S independent manner. Finally, we show that genetic ablation of both cathepsins B and S modulates MHC-II processing and presentation of MOG, and protects mice from EAE.

Materials and Methods

Mice and cells

C57BL/6 (Wild type, WT) and C57BL/6-Tg (Tcra2D2,Tcrb2D2) 1Kuch/J (2D2) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). (2D2 mice express a transgenic CD4+ T cell receptor (Vβ11 TCR/Vα3.2 TCR) that is specific for the I-Ab immunodominant MOG35-55 peptide). Mice deficient in cathepsin B [28], cathepsin S [29], cathepsin L [6], cathepsin B/S, and cathepsin S/L were provided by Dr. Yan Shi of the University of Calgary. All mice used were fully backcrossed to C57BL/6, bred in-house under identical husbandry conditions and genotyped by PCR to confirm gene deletion before use [6, 28, 29]. Animal research was performed according to protocols approved by the University of Calgary Animal Care and Use Committee (M11029) and in accordance with the Canadian Council of Animal Care. Euthanasia was conducted by CO2 inhalation according to approved standard operating procedures. Mice were anesthetized with a ketamine-xylazine mixture according to approved standard operating procedures. All animal work in this study was specifically approved (M11029) by the University of Calgary Animal Care and Use Committee. BMMØs were derived from bone marrow of 8–12 week old male mice using L-929-conditioned media as a
source of M-CSF over a period of 10–14 days as previously described [30–34]. QPCR confirmed relative levels or absence of specific cathepsin mRNA in BMMØ cultures (S1 Protocol, S1 Fig). BMMØs were activated overnight (18 h) with recombinant IFNγ (100 U/ml, PeproTech) before antigen presentation assays. EAE studies were conducted using 8 and 10 week old female mice that were age matched within experiments [24, 35, 36].

Flow cytometry

Flow cytometry data was acquired using a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and analyzed using FLOWJO software v8.6 (Tree Star, Ashland, OR, USA). Leukocyte populations were selected using forward scatter/side scatter (FSC/SSC). All antibodies were purchased from BD Biosciences.

Assessment of antigen processing and presentation

To determine if BMMØs from cathepsin-deficient mice are capable of presenting murine MOG antigens to 2D2 CD4+ T cells, BMMØs derived from WT and cathepsin B, S, L, B/S, or S/L deficient mice were exposed to the immunodominant I-Ab epitope murine MOG35-55 (0, 1, 10, 25 μg/ml; 0.39–9.7 nM), or to the full extracellular domain of murine MOG (MOG1-125; 0, 1, 10, 25 μg/ml; 0.039–0.96 nM) [31, 34, 37, 38], for 6 h within culture medium. Cultures without BMMØs or MOG, or with concanavalin A (ConA, 5 μg/ml) treatment, were included as negative and positive controls for specific presentation and T cell proliferation respectively. MOG35-55 was synthesized by the University of Calgary Peptide Services, Calgary, AB, Canada. MOG1-125 was prepared and characterized as previously described [34]. In brief, MOG1-125 was cloned with a carboxy-terminal 6xHisTag, and expressed using Rosetta blue (DE3) E.coli [34]. The tagged protein was purified using Ni-NTA agarose beads (Qiagen). Endotoxin was removed using endotoxin Affisorbant agarose (polymyxin B Separapre; Bioworld, Dublin, OH, USA). Where indicated BMMØs were treated with the cathepsin inhibitor LHVS (5 μg/ml: morpholinurea-leucine-homophenylalanine-vinyl-phenyl-sulfone; PolyPeptide Laboratories, Strasbourg, France) or vehicle (dimethyl sulfoxide; DMSO) for 18 h before exposure to MOG antigens [12]. Where indicated, phorbol 12-myristate 13-acetate (PMA 50 ng/ml PMA) and ionomycin (1 μg/ml) (PI) was used as a positive control for CD4+ T cell activation. Following antigen exposure, BMMØs were washed extensively to remove all extracellular MOG antigen, and naïve 2D2 splenocytes were incubated with the BMMØs for 16 h. The presentation efficiency of MOG35-55 was determined by measuring the surface expression of two T cell early activation markers on the MOG35-55-specific CD4+ 2D2 T cells via flow cytometry according to standard practices: CD69 (the first inducible surface protein recruited during CD4+ T cell activation) and CD25 (the IL-2 receptor alpha subunit) [34, 39]. Surface expression of MHC-II (I-Ab) on BMMØs was measured by flow cytometry and represented using the mean fluorescent intensity (MFI) relative to WT control samples. Cell viability and surface expression of CD45, B7.2, and CD11b were assessed in LHVS-treated BMMØs using standard trypan blue exclusion and flow cytometric assays respectively.

Fluorometric analysis of cysteine cathepsin activities

Fluorometric determination of cathepsins B, S and L activities was achieved by incubation of recombinant human cathepsins B, S, and L (Novoprotein, Summit, NJ, USA) with their respective specific fluorogenic substrates (Cat B: ZLR-AMC (R&D Systems, Minneapolis, MN, USA)); Cat L/S: Ac-HRYR-ACC (Calbiochem, Etobicoke, ON, Canada)) and increasing concentrations of LHVS (0.1563, 0.3125, 0.625, 1.25, 2.5, 5 μg/ml) in an assay buffer (20 mM sodium acetate pH 5.5 containing 0.675 mM KCl, 0.25 mM CaCl2, 0.125 mM MgCl2)
supplemented with 500 μM L-cysteine:cystine (600:1 molar ratio) at 37°C in a FLUOstar Optima fluorescent plate reader (BMG Labtech, Ortenberg, Germany) as previously described [34, 40]. Relative hydrolytic activities were determined by calculating the slopes of the increasing substrate fluorescence \( y = mx+c \); where \( y \) indicates relative fluorescence, \( m \) indicates slope, \( x \) indicates time) of the initial reaction (20 min) and expressed relative to uninhibited samples.

Induction of EAE

EAE was induced using standard protocols as previously described [24, 34, 35]. Briefly, 8–10 week old female WT and cathepsin B, S, L or B and S deficient mice were anesthetised with ketamine-xylazine. These mice were subsequently injected subcutaneously with 200 μl of an emulsion of 50 μg MOG35-55 in complete Freund’s adjuvant (0.5 mg/ml M. butyricum in paraffin oil) (CFA) (BD Difco, Franklin Lakes NJ, USA). Pertussis toxin (PT) (300 ng) (List Biological laboratories Inc., Campbell CA, USA) was injected intraperitoneally (I.P.) (pH = 7, in saline) on days 0 and day 2. Mice were clinically scored and weighed daily for 40 days using a standard scoring system (score 0—asymptomatic; 0.5—tail weakness; 1—limp tail; 1.5—hind limb limp ing; 2—hind limb weakness; 2.5—partial hind limb paralysis; 3—complete hind limb paralysis; 3.5—hind limb paralysis with forelimb weakness; 4—forelimb paralysis; 4.5–5—complete morbidity/death) [24, 34]. Mice were euthanized if they reached a clinical score of 4. A second group of mice was sacrificed 15 days post injection and their spinal cords were removed for analysis by flow cytometry [24, 34, 41]. Mice injected with CFA and PT in the absence of MOG35-55 did not develop clinical symptoms of EAE (S2 Fig). Where indicated, LHVS (25 mg/kg in 10 μl) or vehicle (DMSO) was injected I.P. daily, starting on the day of MOG immunization, in WT and cathepsin S deficient mice [16]. These mice were sacrificed at day 18 for analysis of spinal cord-infiltrating leukocytes.

EAE spinal cord leukocyte analysis and immune profiling

Spinal cord-infiltrating and resident leukocytes were isolated from mouse spinal cords 15 or 18 days post injection with MOG35-55 using a discontinuous Percoll gradient as previously described [34, 36]. Cells were enumerated using a haemocytometer before being immunostained for macrophages (CD11b+/CD45+ high), microglia (CD11b+/CD45+ low), CD4+ T cells (CD4+/CD3+), CD8+ T cells (CD8+/CD3+), and B cells (B220+/CD45+) and analyzed by flow cytometry [34]. Cells were gated based on live leukocytes followed by their respective cell marker/s and represented as absolute numbers (a function of proportion of each cell type and total number of cells isolated for that tissue) as previously described [34] (S3 Fig). To compare CD4+ T cell development in naïve WT, cathepsin L deficient and cathepsin B/S deficient mice, absolute numbers of CD8+ and CD4+ T cells were enumerated in the spleen, inguinal lymph nodes (LN) and thymus as described for the spinal cord tissue above (S3 Fig) [6].

Statistics

Statistical analyses were completed by one-way ANOVA (or unpaired Student’s t test) with a Tukey test (p<0.05). Analyses of clinical data were done using a Kruskal-Wallis test (Dunn’s multiple comparisons) of mean clinical score for each day, in addition to the total area under the curve [34]. Statistical analyses were completed using GraphPad Prism software (La Jolla, CA, USA).
Results

BMMØs deficient in cysteine cathepsin B, S, or L can efficiently process and present MOG via MHC-II

Since it has been shown that cysteine cathepsins are involved in MHC-II restricted antigen presentation, and that macrophages are the primary APC responsible CD4+ T cell reactivation in the CNS during EAE [21, 23], we set to determine if BMMØs deficient in cathepsin B, S, or L could efficiently process and present MHC-II-restricted MOG antigens. Specifically we measured the ability of BMMØs deficient in individual cysteine cathepsins, to process and present the I-Ab immunodominant MOG35-55 epitope to MOG35-55-specific 2D2 transgenic CD4+ T cells. In brief, BMMØs were incubated for 6 h with the pre-processed MOG35-55 peptide or the whole antigen MOG1-125, and subsequently co-incubated with 2D2 CD4+ T cells for 16 h. Activation of 2D2 CD4+ T cells was assessed by examining surface marker CD69, which is an indicator of early T cell activation [34, 39, 42, 43]. When pulsed with the pre-processed MOG35-55 peptide antigen, BMMØs deficient in cathepsin B, S, or L activated the MOG35-55-specific 2D2 CD4+ T cells as efficiently as WT BMMØs, indicating that these mice are equally capable of presenting pre-processed peptide in the context of MHC-II (Fig 1A). Similarly, when these BMMØs were incubated with the unprocessed antigen MOG1-125, they stimulated equivalent levels of CD69 on 2D2 CD4+ T cells, indicating no overt deficiency in MOG processing in the absence of one of these cysteine proteases (Fig 1B–1D). Similar results were obtained using CD25 as an alternative marker of T cell activation (S4 Fig).

Mice deficient in either cathepsin B or S are susceptible to MOG-induced EAE, while mice deficient in cathepsin L are protected from EAE due to a systemic CD4+ T cell deficiency

Given that BMMØs deficient in cathepsin B, S, or L can process and present MOG35-55 from MOG1-125, we assessed the susceptibility of mice deficient in these cathepsins to MOG-driven EAE. As anticipated, EAE elicited in mice deficient in cathepsins B or S was not clinically (Fig 2A–2C) or immunologically (Fig 2D, S3 Fig) distinguishable from EAE in WT mice. Mice deficient in cathepsin L however were almost completely protected from EAE. Mice deficient in cathepsin L had a significantly reduced clinical score (Fig 2A), 4 fold lower incidence (Fig 2B), and a five day delay (Fig 2C) when compared to WT and cathepsin B or S deficient mice. This correlated with an approximate 10 fold reduction in macrophages, microglia, CD4+ T cells, CD8+ T cells, and B cells isolated from the spinal cords of mice that were sacrificed at day 15 post-inoculation (Fig 2D). Since cathepsin L has been previously shown to be critical for positive thymic selection of CD4+ T cells, we enumerated T cells within the thymus, spleen, and LNs of uninoculated cathepsin L-deficient mice [6]. As previously reported, we found that mice deficient in cathepsin L, but not mice deficient in cathepsin B or S, had significantly reduced numbers of CD4+ T cells in these lymphoid tissues (Fig 2E, S3 Fig) [6]. Since EAE in C57BL/6 mice is primarily mediated by CD4+ T cells, defective thymic selection in these mice is most likely responsible for the observed protection from EAE. Nevertheless, the observation that mice deficient in cathepsin B or S are susceptible to EAE led us to revisit the previously observed protection from EAE by specific pharmacological inhibition of these individual enzymes.
LHVS treatment prevents efficient MHC-II restricted antigen presentation of MOG antigens, and prevents development of EAE in a cathepsin S independent manner.

It has been previously reported that pharmacological inhibition of cathepsin S by compounds such as LHVS, compromises the efficiency of antigen presentation of ovalbumin and protects mice from MOG-induced EAE [12, 16]. Since we found that mice deficient in cathepsin S are susceptible to EAE and have APCs that can efficiently present MOG antigens, we set to...
reconcile these findings by investigating the effect of LHVS, on MOG processing and susceptibility to EAE in WT and cathepsin S deficient mice. BMMØs derived from WT and cathepsin S deficient mice were pre-incubated with LHVS (or vehicle) and assessed for MHC-II surface levels as well as their ability to process and present MOG to 2D2 CD4+ T cells. LHVS treatment of BMMØs significantly reduced their surface expression of MHC-II without affecting surface expression of B7.2, CD45, or CD11b or viability (Fig 3A; S5 Fig). Additionally, LHVS
Fig 3. LHVS treatment reduces MHC-II surface expression and MHC-II restricted presentation efficiencies of MOG antigens in BMMØ, and protects from EAE in WT and cathepsin S deficient mice. (A-C) WT and cathepsin S (Cat S−/−) deficient BMMØ were treated with LHVS (5μg/ml) or DMSO (carrier) for 18 h before assessment of (A) MHC-II surface expression (I-Ab quantified by MFI) or their ability to activate MOG35-55-specific CD4+ T cells following incubation with (B) MOG35-55 peptide (0, 1, 10, 25 μg/ml), (C) MOG1-125 (0, 1, 10, 25 μg/ml), or (D) PMA (50 ng/ml) and ionomysin (1 μg/ml) (PI). Activation of Cysteine Cathepsin Redundancy in EAE
treatment of BMMØs ablated their ability to present either processed (MOG\textsubscript{35-55}) or unprocessed (MOG\textsubscript{1-125}) antigen, in a cathepsin S independent manner (Fig 3B and 3C; S4 Fig, S6 Fig). LHVS did not directly impact T cell activation in response to PI (Fig 3D). Treatment of the BMMØs with the cysteine cathepsin inhibitors E-64d and leupeptin also attenuated efficiencies of MOG presentation (S7 Fig). Consistent with previous reports, daily injections of LHVS completely prevented the clinical onset of EAE in WT mice (Fig 3E and 3F)\cite{16}. Intriguingly, mice deficient in cathepsin S were equally protected from EAE by LHVS treatment, suggesting that LHVS protection is either independent of cathepsin S, or that LHVS-mediated inhibition of multiple cysteine cathepsins is necessary for protection from EAE. Indeed, in reconstituted assays we found that LHVS inhibited the activities of cysteine cathepsins B and L as efficiently as cathepsins S (Fig 3G).

Deficiency of both cathepsins B and S reduces MHC-II restricted presentation of MOG antigens and prevents development of EAE

To determine whether presentation of MOG and susceptibility to EAE would be modulated by the absence of multiple cysteine cathepsins, we generated mice deficient in both cathepsin S and cathepsin B. BMMØs derived from these mice (cathepsin B\textsuperscript{-/-}S\textsuperscript{-/-}) had significantly lower surface expression of MHC-II and reduced abilities to present MOG antigens to 2D2 CD4\textsuperscript{+} T cells (Fig 4A–4C, S4 Fig, S6 Fig). Accordingly, the cathepsin B\textsuperscript{-/-}S\textsuperscript{-/-} mice were protected from EAE, exhibiting lower clinical scores, delayed onset of disease and fewer infiltrating leukocytes isolated from spinal cord tissue (Fig 4D–4F). Since the absence of cathepsin L leads to overt CD4\textsuperscript{+} T cells deficiencies, EAE was not explored in mice deficient in both cathepsin S and cathepsin L, however BMMØs derived from cathepsin S\textsuperscript{-/-}L\textsuperscript{-/-} mice displayed similarly reduced MOG presentation efficiencies as those derived from cathepsin B\textsuperscript{-/-}S\textsuperscript{-/-} mice (S8 Fig). Together these findings indicate that mice are able to present MHC-II antigens and generate a robust CD4\textsuperscript{+} T cell immune response in the absence of cathepsin S, but not when combined with the absence of other cysteine cathepsins.

Discussion

This work adds to the growing collection of studies that demonstrate a functional redundancy between the lysosomal cysteine cathepsins B, S and L with respect to antigen processing, antigen presentation, and autoimmunity\cite{11,34}. While previous studies have explored pharmacologic inhibition of cysteine cathepsins in murine EAE, this is the first study to directly examine the roles of individual cathepsins in MOG processing and EAE by utilizing mice genetically deficient in specific cysteine cathepsins. In this study BMMØs derived from mice deficient in cathepsins B, S, or L were capable of efficiently presenting the I-Ab-immunodominant MOG epitope, and mice deficient in cathepsin B or S were fully susceptible to EAE. Unsurprisingly, mice deficient in cathepsin L were protected from EAE presumably owing to the previously-described thymic immunodeficiency\cite{6}. We additionally demonstrated that LHVS, a reportedly selective inhibitor of cathepsin S, protected mice from EAE but did so independently of
Deficiencies in both cathepsins B and S led to significantly reduced MHC-II expression and MOG antigen presentation efficiency, and protection from EAE. Although the effect of cathepsin deficiency/inhibition on the efficiency of MOG/MHC-II presentation is not directly addressed in the provided text, the role of cathepsin S [12, 16] in MHC-II surface expression and MOG antigen presentation is highlighted. The data from Figure 4 show that BMMØ deficient in both cathepsins B and S have reduced MHC-II surface expression and presentation of MOG antigens, and mice deficient in both cathepsins B and S are protected from EAE.
processing and presentation correlated with EAE susceptibility in this study, it is possible that
alteration of other cathepsin-dependent processes contributed to the EAE phenotypes ob-
served. Nonetheless, these findings suggest that the inhibition of multiple cysteine cathepsins
(via broad spectrum pharmacologic inhibition) may be necessary to attenuate certain autoim-
mune diseases.

Although mice deficient in cathepsins B or S generally have functional immune systems,
several studies have suggested non-redundant roles for cathepsin S in the context of particular
models of autoimmunity [7, 10, 12, 15, 16]. Changes in cathepsin B activity have also been im-
plicated in numerous neurologic autoimmune diseases [19, 44–46]. In the context of MOG-in-
duced EAE in C57BL/6 (I-Ab) mice, we found that the ablation of cathepsin B activity has no
effect on the EAE pathogenesis or MOG antigen processing and presentation by macrophages
[19, 44–46]. These results support the previous findings that splenocytes deficient in cathepsin
B are still capable of presenting antigens via MHC-II [28]. Unlike cathepsin B, cathepsin S has
been shown to be necessary for efficient presentation of a variety of antigens in DCs and B cells
which do not typically express cathepsin L, [4, 7, 11, 20, 34, 47, 48]. Correspondingly cathepsin
S deficient mice were protected from collagen induced arthritis (CIA), which requires robust B
cell and DC responses for clinical progression [7, 49]. In contrast to CIA, it has been shown
that macrophages are the key APCs for reactivation of CD4+ T cells during demyelination in
the CNS of C57BL/6 mice in EAE [11, 21, 23]. Since cathepsin L and S share similar cleavage
sites and are coexpressed by macrophages, unlike B cells and DCs, it is possible that cathepsin
L activity compensates for the absence of cathepsin S in these critical APCs for EAE [7, 11, 34].
Indeed, we demonstrated that BMMØs deficient in either cathepsin S or cathepsin L can effi-
ciently process and present MOG in I-Ab, but not in the absence of both enzymes. Moreover,
we showed that loss of cathepsin B in addition to cathepsin S also compromised antigen pre-
sentation. Together these data suggest that cathepsin B and cathepsin L are both necessary, but
not individually sufficient, to compensate for the loss of cathepsin S in macrophages. This was
supported by the observations that mice deficient in either cathepsin S or cathepsin B, but not
both, were susceptible to EAE.

LHVS, among other cathepsin S inhibitors, has been shown to attenuate EAE [12, 16]. Our
results demonstrate that LHVS, although being commonly referred to as a selective cathepsin S
inhibitor [12, 16, 50], can efficiently inhibit cathepsin B and L. Indeed, LHVS treatment of
macrophages lowered MHC-II surface expression and abolished MOG antigen presentation in-
dependently of cathepsin S. Unsurprisingly LHVS protected both WT and cathepsin S-defi-
cient mice from EAE [16]. These findings suggest that the specific inhibition of cathepsin S by
LHVS is insufficient to protect from EAE, and that the compound’s inhibition of multiple cysteine
cathepsins is necessary for its therapeutic action.

Cathepsin S has been considered a potential therapeutic target in human autoimmune dis-
orders such as MS for over 30 years [7, 10, 16, 26, 51]. Despite this interest, numerous autoim-
mune clinical trials targeting cathepsin S have failed to show clinical efficacy, and patent
applications for cathepsin S inhibitors have declined in the last decade [27]. Our findings,
derived from the analysis of cathepsin deficient mice, suggest that targeting individual cysteine
cathepsins, such as cathepsin S, may not be sufficient to inhibit macrophage-driven autoim-
mune processes, and that the functional redundancies between cysteine cathepsins need to be
considered for future therapeutic strategies targeting these enzymes.

Supporting Information

S1 Fig. Conformation of cathepsin deficiency in BMMØs. Cathepsin B, S, and L mRNA lev-
els in WT, cathepsin B (Cat B−/−), cathepsin S (Cat S−/−), cathepsin L (Cat L−/−) deficient
BMMOs. Average mRNA expression levels quantified by QPCR, are presented relative to WT controls (n = 3). mRNA levels normalized to 18S. Data presented as mean +/- SEM (ANOVA, p < 0.05); significant differences from WT BMMOs are denoted by asterisks (*).

(PPTX)

S2 Fig. Mice inoculated with CFA/PBS/PT do not exhibit clinical or immunological symptoms of EAE. Clinical scoring of EAE severity after inoculation of WT mice with 50μg MOG35-55 in CFA (WT) or PBS in CFA (WT mock) (day 0) and 300 ng pertussis toxin (day 0 and 2) for 40 days (N = 9). Numbers of macrophages (MØ, CD11b+/CD45+), microglia (MG, CD11b+/CD45 low), CD4+ T cells (CD4+/CD3+), CD8+ T cells (CD8+/CD3+) and B cells (B220+/CD45+) isolated from the spinal cord (via a discontinuous percoll gradient) of mice 15 days following inoculation with MOG35-55 (n = 3). Data presented as mean +/- SEM; significant differences (Clinical data, Kruskal-Wallis; unpaired students t-test, p < 0.05) from the WT internal control are denoted by asterisks (*).

(PPTX)

S3 Fig. Flow cytometry gating strategies for cells isolated from the spinal cord, and thymus, spleen, and inguinal lymph node (LN). Infiltrating and resident leukocytes were isolated from mouse spinal cords 15 or 18 days post injection with MOG35-55 using a discontinuous Percoll gradient. Cells were counted with a haemocytometer before being immunostained for markers of macrophages (CD11b+/CD45+ high), microglia (CD11b+/CD45+ low), CD4+ T cells (CD4+/CD3+), CD8+ T cells (CD8+/CD3+) and B cells (B220+/CD45+), and analyzed by flow cytometry. To compare lymphocyte development between WT, cathepsin L- and cathepsin B/S-deficient mice, leukocytes were isolated from spleens, lymph nodes and thymuses of naïve mice using a discontinuous Percoll gradient and immunostained for markers of CD4+ T cells (CD4+/CD3+) and CD8+ T cells (CD8+/CD3+) and analyzed by flow cytometry.

(PPTX)

S4 Fig. Analysis of antigen presentation using CD25 as an alternative marker for CD4+ T cell activation generated equivalent results to those found via evaluation of CD69 expression. WT, WT LHVS treated, cathepsin B (Cat B−/−), cathepsin S (Cat S−/−), cathepsin L (Cat L−/−), or cathepsin B and S (Cat B−/−S−/−) deficient BMMÔ were incubated for 6 h with MOG35-55 peptide (0, 1, 10, 25 μg/ml) or MOG1-125 (0, 1, 10, 25 μg/ml). Activation of MOG35-55-specific 2D2 CD4+ T cells was determined by surface expression of CD25 after 16 h exposure to the BMMÔs. Representative flow cytometry plots for WT, cathepsin B (Cat B−/−), cathepsin S (Cat S−/−), cathepsin L (Cat L−/−) deficient BMMÔ incubated with MOG35-55 (25 μg/ml) or MOG1-125 (25 μg/ml). Data represent 3 independent experiments. Data presented as mean +/- SEM (ANOVA, p < 0.05); significant differences from internal WT controls are denoted by asterisks (*).

(PPTX)

S5 Fig. BMMÔ treated with 5 μg/ml LHVS do not exhibit modified cell survival, or surface expression of CD11b, CD45, or B7.2. Cells were exposed to LHVS for 24 h (5 μg/ml unless otherwise indicated) and assessed for cell viability by trypan blue exclusion using standard protocols. Surface expression of CD11b, CD45, and B7.2 were analyzed by flow cytometry following immunostaining of the treated BMMÔs. Data represent 3 independent experiments. Data presented as mean +/- SEM (ANOVA, p < 0.05); significant differences from internal WT controls are denoted by asterisks (*).

(PPTX)
S6 Fig. Representative flow cytometry plots for Figs 3 and 4. Activation of MOG\textsuperscript{35-55}-specific 2D2 CD4\textsuperscript{+} T cells was determined by surface expression of CD69 after 16 h incubation with WT, LHVS-treated or cathepsin B\textsuperscript{−/−} S\textsuperscript{−/−} BMMØ that had been previously pulsed with 25 μg/ml MOG\textsuperscript{35-55} or no peptide (NP).

S7 Fig. Inhibition of cysteine cathepsins reduces MHC-II restricted presentation efficiencies of MOG antigens in BMMØ. WT BMMØ were treated overnight with DMSO vehicle (untreated), E-64d (10 μg/ml) and leupeptin (2.5 μg/ml) and were subsequently incubated for 6 h with MOG\textsuperscript{35-55} peptide (0, 10, 25 μg/ml) or MOG\textsuperscript{1-125} (0, 10, 25 μg/ml). Activation of MOG\textsuperscript{35-55}-specific 2D2 CD4\textsuperscript{+} T cells was determined by surface expression of CD69 after 16 h exposure to the pulsed and washed BMMØs. Representative flow cytometry plots of no peptide (NP), or 25 μg/ml MOG\textsuperscript{35-55}. Percentage of live BMMØ (as evaluated by trypan blue exclusion) after 24 h exposure to E-64d (10 μg/ml) and Leupeptin (2.5 μg/ml). Data represent 3 independent experiments. Data presented as mean +/- SEM (ANOVA, p<0.05); significant differences from internal WT controls are denoted by asterisks (*).

S8 Fig. BMMØ deficient in both cathepsin S and L have reduced MHC-II restricted presentation efficiencies of MOG antigens. BMMØ derived from WT mice and mice deficient in both cathepsin S and L (Cat S\textsuperscript{−/−}L\textsuperscript{−/−}) were examined for their ability to activate MOG\textsuperscript{35-55}-specific CD4\textsuperscript{+} T cells following incubation with MOG\textsuperscript{35-55} peptide (0, 10, 25 μg/ml) or MOG\textsuperscript{1-125} (0, 10, 25 μg/ml). Activation of MOG\textsuperscript{35-55}-specific 2D2 CD4\textsuperscript{+} T cells was determined by surface expression of CD69 after exposure to the pulsed and washed BMMØs. Data represent 4 independent experiments. Data presented as mean +/- SEM; significant differences (unpaired students t-test, p<0.05) from the WT internal control are denoted by asterisks (*).

S1 Protocol. RNA extraction, cDNA synthesis and real-time polymerase chain reaction (QPCR). Methods for RNA extraction, cDNA synthesis, and QPCR of cathepsin mRNA levels in WT and cathepsin deficient BMMØs shown in S1 Fig.

Acknowledgments

We would like to thank Dr. Yan Shi of the University of Calgary for generously providing the cathepsin deficient mice used in this study.

Author Contributions

Conceived and designed the experiments: EA RY. Performed the experiments: EA RY. Analyzed the data: EA RY. Contributed reagents/materials/analysis tools: EA RY. Wrote the paper: EA RY.

References

1. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des. 2007; 13(4):387–403. Epub 2007/02/22. PMID: 17311556.

2. Haves-Zburof D, Pappeda T, Gour-Lavie A, Mandel I, Glass-Marmor L, Miller A. Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis. J Cell Mol Med. 2011; 15(11):2421–9. Epub 2010/12/15. doi: 10.1111/j.1582-4934.2010.01229.x PMID: 21143385.
3. Stoelke C, Quecke P, Ruckrich T, Burster T, Reich M, Weber E, et al. Cathepsin S dominates autoantigen processing in human thymic dendritic cells. J Autoimmun. 2012; 38(4):332–43. Epub 2012/03/20. doi: 10.1016/j.jaut.2012.02.003. S0896-8411(12)00026-1 [pii]. PMID: 22424724.

4. Beers C, Honey K, Fink S, Forbush K, Rudensky A. Differential regulation of cathepsin S and cathepsin L in interferon gamma-treated macrophages. J Exp Med. 2003; 197(2):169–79. Epub 2003/01/23. PMID: 12538657; PubMed Central PMCID: PMC2193812.

5. Honey K, Duff M, Beers C, Brissette WH, Elliott EA, Peters C, et al. Cathepsin S regulates the expression of cathepsin L and the turnover of gamma-interferon-inducible lysosomal thiol reductase in B lymphocytes. J Biol Chem. 2001; 276(25):22573–8. Epub 2001/04/18. doi: 10.1074/jbc.M101851200.M101851200 [pii]. PMID: 11306582.

6. Nakagawa T, Roth W, Wong P, Nelson A, Farr A, Deussing J, et al. Cathepsin L: critical role in invariant chain degradation and CD4+ T cell selection in the thymus. Science. 1998; 280(5362):450–3. Epub 1998/05/09. PMID: 9545226.

7. Nakagawa T, Brissette WH, Lira PD, Griffiths RJ, Petrushova N, Stock J, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity. 1999; 10(2):207–17. Epub 1999/03/11. doi: S1074-7613(00)80021-7 [pii]. PMID: 10072073.

8. Manoury B, Mazzeo D, Fugger L, Viner N, Ponsford M, Streeter H, et al. Destructive processing by asparaginyl endopeptidase limits presentation of a dominant T cell epitope in MBP. Nat Immunol. 2002; 3(2):169–74. Epub 2002/01/29. doi: 10.1038/nij754nij754 [pii]. PMID: 11812994.

9. Belizaire R, Unanue ER. Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation. Proc Natl Acad Sci U S A. 2009; 106(41):17463–8. Epub 2009/10/07. doi: 10.1073/pnas.0908583106.0908583106 [pii]. PMID: 19805168; PubMed Central PMCID: PMC2752404.

10. Baugh M, Black D, Westwood P, Kinghom E, McGregor K, Bruin J, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity. 1999; 10(2):207–17. Epub 1999/03/11. doi: S1074-7613(00)80021-7 [pii]. PMID: 10072073.

11. Hsing LC, Rudensky AY. The lysosomal cysteine proteases in MHC class II antigen presentation. Immunol Rev. 2005; 207:229–41. Epub 2005/09/27. doi: IMR310 [pii]. PMID: 16181340.

12. Riese RJ, Mitchell RN, Villadangos JA, Shi GP, Palmer JT, Karp ER, et al. Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest. 1998; 101(11):2351–63. Epub 1998/06/17. doi: 10.1172/JCI1158 PMID: 9616206; PubMed Central PMCID: PMC508824.

13. Honey K, Nakagawa T, Peters C, Rudensky A. Cathepsin L regulates CD4+ T cell selection independently of its effect on invariant chain: a role in the generation of positively selecting peptide ligands. J Exp Med. 2002; 195(10):1349–58. Epub 2002/05/22. PMID: 12021314; PubMed Central PMCID: PMC2193748.

14. Lockwood TD. Cathepsin B responsiveness to glutathione and lipoic acid redox. Antioxid Redox Signal. 2002; 4(4):681–91. Epub 2002/09/17. doi: 10.1089/1523086026220193 PMID: 12230881.

15. Desai SN, White DM, O’Shea K M, Brown ML, Cywin CL, Spero DM, et al. An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity. Eur J Pharmacol. 2006; 538(1–3):168–74. Epub 2006/04/25. doi: S0014-2999(06)00322-0 [pii]. PMID: 16631730.

16. Fissolo N, Kraus M, Reich M, Ayturman M, Overkleeft H, Driessen C, et al. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur J Immunol. 2008; 38(9):2401–11. Epub 2008/09/16. doi: 10.1002/eji.200838413 PMID: 18792018.

17. Liu JP, Petanceska SS, Devi LA. Neurotrophic factors regulate cathepsin S in macrophages and microglia: A role in the degradation of myelin basic protein and amyloid beta peptide. Mol Med. 1999; 5(5):334–43. Epub 1999/07/03. doi: 0130 [pii]. PMID: 10390549; PubMed Central PMCID: PMC2230424.

18. Beck H, Schwarz G, Schroter CJ, Deeg M, Baier D, Stevanovic S, et al. Cathepsin S and an asparaginyl-specific endopeptidase dominate the proteolytic processing of human myelin basic protein in vitro. Eur J Immunol. 2001; 31(12):3726–36. Epub 2001/12/18. doi: 10.1002/1521-4111(200112)31:12<3726::AID-IJIM3726>3.0.CO;2-O [pii].10.1002/1521-4111(200112)31:12<3726::AID-IJIM3726>3.0.CO;2-O. PMID: 11745393.

19. Bever CT Jr., Panitch HS, Johnson KP. Increased cathepsin B activity in peripheral blood mononuclear cells of multiple sclerosis patients. Neurology. 1994; 44(4):745–8. Epub 1994/04/01. PMID: 8164836.
20. Hsieh CS, deRoos P, Honey K, Beers C, Rudensky AY. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation. J Immunol. 2002; 168(6):2618–25. Epub 2002/03/09. PMID: 11884425.

21. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol. 2009; 9(6):393–407. Epub 2009/05/16. doi: 10.1038/nri2550 PMID: 19444307; PubMed Central PMCID: PMC2813731.

22. Nakahara J, Aiso S, Suzuki N. Autoimmune versus oligodendrogliopathy: the pathogenesis of multiple sclerosis. Arch Immunol Ther Exp (Warsz). 2010; 58(5):325–33. Epub 2010/08/03. doi: 10.1007/s00005-010-0094-x PMID: 20676785.

23. Yamasaki R, Lu H, Butovsky O, Ohno N, Rietsch AM, Cialic R, et al. Differential roles of microglia and monocytes in the inflamed central nervous system. J Exp Med. 2014; 211(8):1533–49. Epub 2014/07/09. doi: 10.1084/jem.20132477/jem.20132477 [pii] PMID: 25002752; PubMed Central PMCID: PMC4113947.

24. Stromnes IM, Goverman JM. Active induction of experimental allergic encephalomyelitis. Nat Protoc. 2006; 1(4):1810–9. Epub 2007/05/10. doi: 10.1038/nprot.2006.285 PMID: 17487163.

25. Podolin PL, Bolognesi BJ, Carpenter DC, Davis TG, Johanson RA, Fox JH, et al. Inhibition of invariant chain processing, antigen-induced proliferative responses, and the development of collagen-induced arthritis and experimental autoimmune encephalomyelitis by a small molecule cysteine protease inhibitor. J Immunol. 2008; 180(12):7988–9003. Epub 2008/06/05. doi: 180/12/7989 [pii] PMID: 18523262.

26. Irie O, Kosaka T, Kishida M, Sakaki J, Masuya K, Konishi K, et al. Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2. Bioorg Med Chem Lett. 2008; 18(19):5280–4. Epub 2008/09/12. doi: 10.1016/j.bmcl.2008.06.096 PMID: 18783943.

27. Lee-Dutra A, Wiener DK, Sun S. Cathepsin S inhibitors: 2004–2010. Expert Opin Ther Pat. 2011; 21(3):31–37. Epub 2011/02/24. doi: 10.1517/13543776.2011.553800 PMID: 21342054.

28. Deussing J, Roth W, Saftig P, Peters C, Ploegh HL, Villadangos JA. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc Natl Acad Sci U S A. 1998; 95(8):4516–21. Epub 1998/05/16. PMID: 9539769; PubMed Central PMCID: PMC22521.

29. Shi GP, Villadangos JA, Drainoff G, Small C, Gu L, Haley KJ, et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity. 1999; 10(2):197–206. Epub 1999/03/11. doi: 10.1016/S1074-7613(00)80020-5 [pii] PMID: 10072072.

30. Rybicka JM, Balce DR, Chaudhuri S, Allan ER, Yates RM. Phagosomal proteolysis in dendritic cells is modulated by NADPH oxidase in a pH-independent manner. EMBO J. 2011; 31(4):435–44. Epub 2011/12/14. doi: 10.1038/emboj.2011.440 PMID: 22157818; PubMed Central PMCID: PMC3280544.

31. Rybicka JM, Balce DR, Khan MF, Krohn RM, Yates RM. NADPH oxidase activity controls phagosomal proteolysis in macrophages through modulation of the lumenal redox environment of phagosomes. Proc Natl Acad Sci U S A. 2010; 107(23):10496–501. Epub 2010/05/26. doi: 10.1073/pnas.0914867107 PMID: 2049862; PubMed Central PMCID: PMC2890838.

32. Savina A, Jancic C, Hugues S, Guermonprez P, Vargas P, Moura IC, et al. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell. 2006; 126(1):205–18. PMID: 16598987.

33. Karasuyama H, Melchers F. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol. 1988; 18(1):97–104. Epub 1988/01/01. doi: 10.1002/eji.1830180115 PMID: 2831066.

34. Allan ER, Tailor P, Balce DR, Pirzadeh P, McKenna NT, Renaux B, et al. NADPH Oxidase Modifies Patterns of MHC Class II-Restricted Epitopic Repertoires through Redox Control of Antigen Processing. J Immunol. 2014; 192(8):4889–5001. Epub 2014/04/30. doi: 10.4049/jimmunol.1302896jimmunol.1302896 [pii] PMID: 24778444.

35. van der Veen RC, Dietlin TA, Hofman FM, Pen L, Segal BH, Holland SM. Superoxide prevents nitric oxide-mediated suppression of helper T lymphocytes: decreased autoimmune encephalomyelitis in nicotinamide adenine dinucleotide phosphate oxidase knockout mice. J Immunol. 2000; 164(10):5177–83. Epub 2000/05/09. PMID: 10799876.

36. Agrawal SM, Silva C, Tourtellotte WW, Yong VW. EMMPRIN: a novel regulator of leukocyte transmigration into the CNS in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci. 2011; 31(2):669–77. Epub 2011/01/14. doi: 10.1523/JNEUROSCI.3659-10.2011 [pii] PMID: 21228176.

37. Balce DR, Li B, Allan ER, Rybicka JM, Krohn RM, Yates RM. Alternative activation of macrophages by IL-4 enhances the proteolytic capacity of their phagosomes through synergistic mechanisms. Blood. 2011; 118(15):4199–208. Epub 2011/08/19. doi: 10.1182/blood-2011-01-328906 PMID: 21846901.
38. Norton WT, Poduslo SE. Myelination in rat brain: method of myelin isolation. J Neurochem. 1973; 21(4):749–57. Epub 1973/10/01. PMID: 4271082.

39. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med. 2003; 197(9):1073–81. Epub 2003/05/07. doi: 10.1084/jem.20021603 PMID: 12732654; PubMed Central PMCID: PMC2193967.

40. Balce DR, Allan ER, McKenna N, Yates RM. gamma-Interferon-inducible lysosomal thiol reductase (GILT) maintains phagosomal proteolysis in alternatively activated macrophages. J Biol Chem. 2014; 289(46):31891–904. Epub 2014/09/26. doi: 10.1074/jbc.M114.584391 [pii]. PMID: 25253686; PubMed Central PMCID: PMC4231668.

41. Choi SH, Lee DY, Chung ES, Hong YB, Kim SU, Jin BK. Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J Neurochem. 2005; 95(6):1755–65. Epub 2005/10/13. doi: JNC3503 [pii] doi:10.1111/j.1471-4159.2005.03503.x PMID: 16219027.

42. Underhill DM, Bassetti M, Rudensky A, Aderem A. Dynamic interactions of macrophages with T cells during antigen presentation. J Exp Med. 1999; 190(12):1909–14. Epub 1999/12/22. PMID: 10601366; PubMed Central PMCID: PMC2195713.

43. Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol. 2003; 81:331–71. Epub 2004/01/09. PMID: 14711059.

44. Govindarajan KR, Clausen J. Regional distribution of cathepsins B 1 and D in human brain. Brain Res. 1974; 67(1):141–6. Epub 1974/02/15. doi: 0006-8993(74)90304-7 [pii]. PMID: 4470412.

45. Govindarajan KR, Offner H, Clausen J, Fog T, Hyllested K. The lymphocytic cathepsins B-1 and D activities in multiple sclerosis. J Neurol Sci. 1974; 23(1):81–7. Epub 1974/09/01. doi: 0022-510X(74)90144-0 [pii]. PMID: 4854938.

46. Kikuchi H, Yamada T, Furuya H, Doh-ura K, Ohyagi Y, Iwaki T, et al. Involvement of cathepsin B in the motor neuron degeneration of amyotrophic lateral sclerosis. Acta Neuropathol. 2003; 105(5):462–8. Epub 2003/04/05. doi: 10.1007/s00401-002-0667-9 PMID: 12677446.

47. Villadangos JA, Riese RJ, Peters C, Chapman HA, Ploegh HL. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J Exp Med. 1997; 186(4):549–60. Epub 1997/08/18. PMID: 9254653; PubMed Central PMCID: PMC2199027.

48. Gresser O, Weber E, Hellwig A, Riese S, Regnier-Vigouroux A. Immunocompetent astrocytes and microglia display major differences in the processing of the invariant chain and in the expression of active cathepsin L and cathepsin S. Eur J Immunol. 2001; 31(6):1813–24. Epub 2001/07/04. doi: 10.1002/1521-4141(200106)31:6<1813::AID-IJMUI1813>3.0.CO;2-8 PMID: 11433378.

49. Brand DD, Kang AH, Rosloniec EF. Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol. 2003; 25(1):9–18. Epub 2003/08/09. doi: 10.1007/s00281-003-0127-1 PMID: 12904888.

50. Fuji H, Ivinson SM, Shimizu H, Kajiwara R, Kariminia A, Yan M, et al. Inhibition of cathepsin S reduces allogeneic T cell priming but not graft-versus-host disease against minor histocompatibility antigens. Biol Blood Marrow Transplant. 2012; 18(4):546–56. Epub 2011/12/20. doi: 10.1016/j.bbmt.2011.11.027 PMID: 22178962.

51. Boehme DH, Umezawa H, Hashim G, Marks N. Treatment of experimental allergic encephalomyelitis with an inhibitor of cathepsin D (pepstatin). Neurochem Res. 1978; 3(2):185–94. Epub 1978/04/01. PMID: 307703.